Ovarian Cancer Biomarkers - DIGE Spot identification
Ontology highlight
ABSTRACT:
INSTRUMENT(S): impact HD
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Blood Serum
DISEASE(S): Malignant Neoplasm Of Ovary
SUBMITTER: 
Florian Weiland
LAB HEAD: Martin K Oehler
PROVIDER: PXD018417 | Pride | 2020-08-26
REPOSITORIES: Pride
Similar Datasets
Project description:Analyzing serological differences between AMA positive and negative PBC using DIGE
2014-11-27 | PXD001152 | Pride
Project description:Low-grade serous ovarian carcinomas are typically Ras-pathway mutated, TP53 wild-type, have limited chromosomal aberration, and are frequently associated with borderline tumors. By contrast, high-grade serous ovarian carcinoma lack Ras-pathway mutations, are invariably TP53 mutated, show widespread genomic change, and are commonly BRCA-pathway disrupted. We sought to identify differences in genomic copy number changes between co-existing borderline and invasive components of serous carcinoma. Paired co-existing borderline and invasive tumor components of ovarian serous carcinoma were sampled and profiled from tumors from 7 patients
2014-10-01 | E-GEOD-57279 | biostudies-arrayexpress
Project description:Low-grade serous ovarian carcinomas are typically Ras-pathway mutated, TP53 wild-type, have limited chromosomal aberration, and are frequently associated with borderline tumors. By contrast, high-grade serous ovarian carcinoma lack Ras-pathway mutations, are invariably TP53 mutated, show widespread genomic change, and are commonly BRCA-pathway disrupted.We sought to identify differences in genomic copy number changes between co-existing borderline and invasive components of serous carcinoma. Paired co-existing borderline and invasive tumor components were sampled and profiled from formalin-fixed paraffin embedded tumors from 6 patients
2014-10-01 | E-GEOD-57276 | biostudies-arrayexpress
Project description:Low-grade serous ovarian carcinomas are typically Ras-pathway mutated, TP53 wild-type, have limited chromosomal aberration, and are frequently associated with borderline tumors. By contrast, high-grade serous ovarian carcinoma lack Ras-pathway mutations, are invariably TP53 mutated, show widespread genomic change, and are commonly BRCA-pathway disrupted. We sought to identify differences in genomic copy number changes in borderline and invasive components of serous carcinoma. Borderline and invasive tumor components were profiled from patients with LGSC
2014-10-01 | E-GEOD-57270 | biostudies-arrayexpress
Project description:Polyandrous ant queens are inseminated early in their life and store sperm mixtures for a potential reproductive life of decades. However, they cannot re-mate later in life and are thus expected to control the loss of viable sperm because their life-time reproductive success is ultimately limited by the viability of sperm obtained in their single reproductive event. In the leaf-cutting ant Atta colombica, we have previously shown that sperm survival is lowered when getting in contact with seminal fluid of other males, and remains stable when in contact with secretions of the queen sperm storage organ (spermatheca). Here we aim to resolve the main protein-level interactions that mediate sperm competition dynamics and sperm preservation. We used artificial insemination and DIGE-based proteomics to identify proteomic changes when seminal fluid is exposed to spermathecal fluid. Seminal fluid was collected from mature males during field season experiments in Panama, by gently squeezing males’ abdomen until the ejaculate came out. Ejaculates from several males were kept together in ice and then centrifuged for 10 minutes at 13,500 g, the supernatant collected in a separate tube and then centrifuged again. The resulting supernatant was then transferred to another tube and stored at -20° C until further use. Four biological replicates of SF were collected from 4 colonies, each consisting of 400 µl SF from approximately 350 males. From each biological replicate three 100 µl aliquots were retrieved, and assigned to one of the following treatments: (1) un-inseminated controls, (2) inseminated SF retrieved after 30 min, and (3) inseminated SF retrieved after 12 h (Fig 1). Next, each of those aliquots was used to artificially inseminate 10 virgin queens (10 µl of aliquot per queen), for a total of 80 queens inseminated. Queens were allowed to recover for 30 min or 12 h before dissecting them to obtain the spermathecal content. All these spermathecal contents were then pooled per treatment and replicate, resulting in a total of 12 samples (3 treatments – un-inseminated SF, inseminated SF retrieved after 30 min inside the queen, and inseminated SF retrieved after 12 hours inside the queen - with 4 biological replicates). Proteins were precipitated in each sample by adding 4 volumes of ice-cold acetone for 4 hours at -20°C and centrifuged at 14,000 g for 10 minutes, after which supernatants were discarded and the protein pellets were stored at -80°C until further use. All of those 12 samples entered the DIGE analysis.
2019-01-03 | PXD011320 | Pride
Project description:Ovarian cancer is one of the leading causes of death from cancer in females, worldwide. An early diagnosis of ovarian carcinoma is likely to improve clinical outcome of patients in terms of reduced morbidity and mortality. The objective of our project is the proteomic analysis of ovarian malignant and non-malignant tissue samples to find potential biomarkers of disease diagnosis and prognosis that can be assessed non-invasively through patient plasma/serum screening. In this project, we have used a methodical approach involving 2-dimensional gel electrophoresis in conjunction with MALDI-TOF MS analysis followed by immunological validation of the selected markers by western blotting and ELISA for identification of biomarkers of ovarian cancer. The associated research paper is in preparation.
2021-09-08 | PXD014352 | Pride
Project description:Genome-wide DNA methylation profiles of TGF-beta ovarian cancer cells were obtained using next generation Illumina Infinium 450k assay which includes over 450,000 GpG sites. DNA from 12 samples were hybridized to the Illumina's Infinium HumanMethylation 450 BeadChip
2015-04-07 | E-GEOD-56621 | biostudies-arrayexpress
Project description:Genome-wide DNA methylation profiles of SGI-110-treated ovarian cancer xenografts were obtained using next generation Illumina Infinium 450k assay which includes over 450,000 GpG sites. DNA from 6 samples were hybridized to the Illumina's Infinium HumanMethylation 450 BeadChip
2014-10-02 | E-GEOD-55613 | biostudies-arrayexpress
Project description:Ovarian cancer is the 5th main cause of death from cancer in females, worldwide. An early and accurate diagnosis of ovarian carcinoma is likely to improve clinical outcome of patients in terms of reduced morbidity and mortality. The objective of our project is the proteome profiling of ovarian malignant and non-malignant tissue samples to find potential biomarkers of disease diagnosis and prognosis. In this project, we have used a systematic protein profiling approach involving 2-dimensional gel electrophoresis coupled with MALDI-TOF MS analysis for identification of biomarkers of ovarian cancer. The associated research paper is in preparation.
2019-11-27 | PXD013827 | Pride
Project description:Identification and validation of potential prognostic biomarkers in older ovarian cancer patients with high-grade serous adenocarcinoma (HGSC)
2020-03-01 | GSE126308 | GEO